Beat
Drug trials, gene editing, and longevity — the science with the caveats intact.
The muscle pills that hid a hormone, and the invisible line every drug walks →
A US peptide company was jailed for selling unapproved muscle pills secretly laced with testosterone, pushing one buyer into psychosis. It is the loudest sign yet of a market that sells drugs with no dose you can trust.
An AI that read 24 million papers points to a new Parkinson's target →
New tools this week all attacked biotech's oldest problem - the space of possible molecules and targets is astronomically large, so the whole game is narrowing the search.
A first drug for the disease where the body attacks its own nerves →
The immune system dominated biotech this week - drugs to calm it in autoimmune disease, and drugs to wake it against cancer it had missed.
A heart drug lowered inflammation exactly as planned - and failed anyway →
Novo Nordisk's ziltivekimab hit its biological target but did not protect the heart, and it raised serious infections - a hard lesson in why the body's defenses resist a simple off switch.
The week medicine kept losing its footrace with resistance →
A phage-therapy result for stubborn urinary infections, two studies of how bacteria dodge antibiotics, and a cancer finding that shows the same escape logic - resistance is the theme running through this week's science.
The weaker drug passed. The stronger one failed. Same FDA week. →
In one week, an FDA advisory panel endorsed Replimune's twice-rejected melanoma drug, which was tested without a control group, and voted down Capricor's Duchenne heart therapy, which ran a full randomised trial. Plus GSK's cost cuts, a J&J cell-therapy bet, another Novo Nordisk stumble, and an Ebola vaccine only a charity would fund.
A blood test for colon cancer, and the rush to catch disease sooner →
The FDA cleared Freenome's blood test to screen for colorectal cancer, part of a wider push to spot disease years earlier. Plus a melanoma drug backed over its own reviewers' doubts, a Duchenne therapy rejected, and a weight-loss drug that cut heavy drinking.
A drug passed its trial. Its stock still fell 60%. →
MapLight's schizophrenia drug hit its main goal and lost two-thirds of its value the same morning, Lilly posted huge weight-loss numbers with murkier heart data, and an FDA panel rejected a Duchenne therapy - three trials this week judged less on whether an effect was real than on how big it was.
Fibromyalgia turns out to be written in the genes, and the brain →
A study across 2.5 million people found 26 genetic signals for fibromyalgia, planting a long-doubted condition firmly in the brain. Plus a weight-loss drug that missed the endpoint it also measured, an FDA fight over a Duchenne trial, and a gene-editing death kept quiet.
An FDA panel backed unproven peptides over its own scientists →
The week's biggest biotech story was a regulatory one - a US panel voting to widen access to barely-tested peptides. Alongside it: two large "linked to" health studies, a weight-loss drug that fell short on the heart, and a record measles year.
Most brain cells turn out to be generalists, not specialists →
A new study finds the brain runs on jack-of-all-trades neurons, not a roster of experts - plus an FDA panel waves through unproven peptides, Lilly's next weight-loss drug, measles at a 35-year high, and a death in a Chinese gene-editing trial.
The hunt for a new drug is a search through billions of molecules →
Pharma is pouring money into AI and supercomputers to sift a chemical space too vast to check by hand. New tools this week narrow the haystack rather than search it faster - while the drugs that survive that hunt still mostly fail downstream.
Four drug programs died this week. One winner took every headline. →
While Eli Lilly's obesity pill hit 22.6% weight loss, four other drug programs were quietly killed off — a phase 3 gene therapy, a sickle cell drug, a cancer radioligand, and an eczema treatment bought for $1.1 billion. Plus a child's death in a China gene-editing trial, safer CAR-T signals, and a US bill to cut animal testing.
The same caffeine is heart-safe in coffee and risky in an energy shot →
A new American Heart Association review finds up to 400 mg of caffeine a day — about three to five cups of black coffee — is safe and may even lower heart risk, while the concentrated caffeine in energy shots raises blood pressure and disrupts heart rhythm.
Two obesity-drug giants are now fighting over whose ad tells the truth →
Novo Nordisk sued Eli Lilly this week over weight-loss ads it calls misleading, turning the year's biggest drug rivalry into a fight about what a head-to-head trial really proves. Elsewhere: a psoriasis pill and a prostate treatment let their data speak, a knee therapy failed, and polio's endgame stalls.
Why evolution never weeded out the genes that make us sick when we're old →
A new analysis argues the diseases of old age persist because the genes behind them helped us reproduce young — as a wave of billion-dollar deals, late-stage failures, and a safer Alzheimer's drug reshaped the week.
Aging may be a cleanup problem — and a Stanford lab just switched the crew back on in mice →
Researchers traced organ aging to the body's failing waste-disposal system, not the damage itself — plus AI-designed gene editors, a psoriasis pill, and a gentler prostate treatment.
A phase 3 drug just sold for $500,000 — the same week its old owner spent billions elsewhere →
A shelved antibiotic changed hands for less than the price of a flat. Across the week, J&J, Mission and Agenus all cut programs that other companies are queuing up to buy — while a 10-year prostate study showed a gentler treatment works and still barely reaches anyone.
Merck's cholesterol pill clears the FDA — the first you can swallow, not inject →
A drug class proven for a decade finally comes as a once-a-day tablet. Plus: a gentler prostate treatment matches surgery, an oral psoriasis pill, and a vaccine aimed at stopping pancreatic cancer before it starts.
You can now bet on whether a drug will pass its trial — and that quietly changes the trial →
A prediction market opened contracts on clinical-trial results and FDA decisions, promising to surface truth the sponsors keep hidden. The same payoff hands a motive to anyone who can move or leak the result. Plus the first cholesterol pill of its kind, and a vaccine aimed at pancreatic cancer before it starts.
An Ebola trial was built in six weeks — while the outbreak's frontline collapses for lack of pay →
A record-fast treatment trial and a new vaccine show what years of pooled preparation can do. Unpaid, attacked burial teams show how quickly coordination breaks at the bottom.
The FDA is publishing the letters that say why drugs get rejected — and the industry is fighting it →
For years a drug rejection was a private letter only the company saw. Now the FDA is posting them, and pharma has filed to stop it. Plus ADCs come for chemo, an Ebola trial races the outbreak, and a heart drug fails.
A drug slowed Alzheimer's by hitting the protein everyone ignored — and still "failed" its own test →
Biogen's anti-tau drug diranersen slowed cognitive decline as well as approved medicines, with fewer risks — yet missed its primary trial goal, because the lowest dose worked best. Plus the Alzheimer's graveyard around it, and a fast-built Ebola vaccine heads into people.
Four children with "universally fatal" brain cancer are alive years after an experimental therapy →
A small trial of a cell therapy kept children with incurable brain tumours alive for years — a phase 1 result, not a cure. Plus the FDA starts publishing its drug rejections again, and three big programs die.
A cancer therapy, taken off a shelf, is turning on the immune system that attacks itself →
Fate's ready-made CAR-T shows early promise in a rare autoimmune disease — while $10B and $1.5B deals reshape the industry and Roche walks away from Huntington's.
A quiet approval for a slow kidney disease — and an immune system we're learning to calm →
The FDA cleared a new drug for IgA nephropathy, a disease that erases kidneys over decades. It sits inside a good week for immune medicine — off-the-shelf cell therapy easing hard autoimmune disease, a 40-year HIV vaccine problem yielding step by step — and a reminder that progress still doesn't reach everyone.
Doctors have replaced the dopamine in Parkinson's for 60 years — now they're trying to replace the cells that make it →
A Lund University trial put lab-grown dopamine cells into eight Parkinson's patients' brains and reported a clean first-year safety record — the first serious attempt to rebuild what the disease destroys rather than top it up. Plus: a hoped-for vaccine benefit collapses under a proper trial, and the FDA quietly stops publishing its drug-rejection letters.
Three big drug programs died this week — and the one that hurts most did everything it was designed to do →
GSK, Roche and AstraZeneca all pulled the plug on programs for the hardest diseases. The Huntington's drug lowered the disease-causing protein exactly as planned — and patients still didn't get better.
A gentler way to clear the bone marrow — and a KRAS lung-cancer race gets a new front-runner →
Scientists found a way to prepare patients for a stem-cell transplant without burning down the whole body first. Plus: Roche's KRAS drug beats its two rivals, Novartis buys into a new cancer weapon, and the WHO says cancer progress is skipping the poor.
Big pharma spent billions this week buying biotechs it could have built →
A run of deals — Vertex's $10bn Crinetics buyout, Novartis, Ipsen, United Therapeutics — shows the giants outsourcing early science to small firms and paying only for winners.
The new US health aid comes with strings — and some African governments are saying no →
Washington is offering African nations billions to build their own health systems, but the money is tied to conditions on data, drugs, and minerals — and several countries are refusing while the WHO-run fight against Ebola in Congo carries on.
The pills that quietly erased obesity's heart-risk gap — and a UK weight-loss tablet hits the shelves →
A large study finds statins and blood-pressure drugs have narrowed obesity's cardiovascular disadvantage to almost nothing, as a swallowable Wegovy reaches UK pharmacies. Plus a KRAS lung-cancer win, a rare-disease bone drug, and a vaccine for a parasite that infects 250 million people.
The third company to crack an "undruggable" cancer target just beat the two that got there first →
Roche's late-arriving lung-cancer drug outperformed Amgen's and Bristol Myers Squibb's in a head-to-head trial — the week's clearest lesson that being first proves a thing is possible, but rarely means you keep the prize.
China clears the first CAR-T for a solid tumor — the wall cancer therapy has hit for 15 years →
A Shanghai biotech won the world's first approval for a CAR-T therapy against a solid tumor, cracking a problem that has stopped the field since 2010 — plus an AI lab that now wants to make its own drugs, a 40-year-old cancer target finally cornered, and a clue to why some brains shrug off Alzheimer's.
The gene-editing drug that doesn't cut the gene — a muscle disease is the first test →
A new kind of therapy changes what a gene does without altering the DNA itself. Early data in three patients with a muscular dystrophy is the first human sign it works. Plus China's first solid-tumor CAR-T, and a wave of rare-disease deals.
The FDA delays a rare-epilepsy drug three months — and analysts blame last year's staff cuts →
A finished drug application sits in a longer queue, as the agency that reviews it runs shorter on people. Plus a gene therapy chief steps down, and a busy week of new results piling up behind them.